EUVIMEDEUVIMED entdecken
Crossref

CYP1A2 and ADH1C contribute to abacavir aldehyde intermediate formation in the human liver

Rei Sato, Masataka Nakano, Yuichiro Higuchi, Shotaro Uehara, Nao Yoneda, Hiroshi Suemizu, Miki Nakajima, Tatsuki Fukami

Drug Metabolism and Disposition · 2026-08 · 54 (8) · 100348

DOI: 10.1016/j.dmd.2026.100348 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Metabolism and Disposition, 2026-08. Verfasst von Rei Sato und 7 weiteren Autor:innen. Beteiligte Einrichtung: Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan. Hauptthemen laut MEDLINE: Dideoxynucleosides, Alcohol Dehydrogenase, Liver, Cytochrome P-450 CYP1A2. Die Arbeit nennt 38 Literaturangaben. Gefördert von: Ministry of Education, Culture, Sports, Science and Technology, Mochida Memorial Foundation for Medical and Pharmaceutical Research, Kanazawa University.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Abacavir, an anti-human immunodeficiency virus agent, is metabolized to the pharmacologically inactive abacavir carboxylate via an aldehyde intermediate, abacavir aldehyde (abacavir-CHO). Because aldehyde formation is generally rate-limiting, the enzymes responsible for abacavir-CHO formation may significantly influence drug efficacy and toxicity. In this study, we aimed to identify the enzymes involved in abacavir-CHO formation in the human liver. Using 5 recombinant human NAD+-dependent alcohol dehydrogenase (ADH) isoforms, which are well known to catalyze aldehyde formation from alcohols, ADH1C was identified as the primary catalyst of abacavir-CHO formation. In human liver S9 fractions, abacavir-CHO formation was observed not only in the presence of NAD+ but also in the presence of NADPH, with intrinsic clearance comparable between the 2 conditions. Notably, NADPH-dependent activity was higher in human liver microsomes than in cytosolic fractions. This activity was markedly inhibited by 1-aminobenzotriazole, a general cytochrome P450 (P450) inhibitor, indicating the involvement of P450 enzymes. Among recombinant human P450 isoforms, CYP1A2 exhibited the highest catalytic activity. Quantitative analysis using the relative activity factor approach revealed that CYP1A2 accounted for 89.8% of abacavir-CHO formation under NADPH-dependent conditions in human liver microsomes. In HepaSH cells, hepatocytes from chimeric mice with humanized livers, abacavir carboxylate formation was decreased by 50% by α-naphthoflavone, a CYP1A2 inhibitor, and increased approximately 7-fold by omeprazole, a CYP1A2 inducer. Collectively, these findings demonstrate that CYP1A2 plays a significant role in abacavir-CHO formation in the human liver, comparable to ADH1C, and may have implications for variability in abacavir response. SIGNIFICANCE STATEMENT: This study demonstrates that CYP1A2, in addition to ADH1C, significantly contributes to the formation of the reactive aldehyde metabolite abacavir-CHO in the human liver. This finding suggests a need to reconsider the conventional view that alcohol dehydrogenases are the primary enzymes responsible for this pathway and indicates that CYP1A2-mediated metabolism may influence interindividual variability, drug-drug interactions, and the risk of abacavir-associated adverse reactions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

DideoxynucleosidesAlcohol DehydrogenaseLiverCytochrome P-450 CYP1A2AldehydesAnti-HIV AgentsHumansAbacavirAnimalsMicrosomes, LiverMiceCytosolHepatocytes

Stichwörter der Autor:innen

AbacavirAlcohol dehydrogenaseAldehyde formationCYP1A2

Substanzen

AbacavirDideoxynucleosidesAlcohol DehydrogenaseCytochrome P-450 CYP1A2CYP1A2 protein, humanADH1C protein, humanAldehydesAnti-HIV Agents

Autor:innen und Institutionen

  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.
  • Liver Engineering Laboratory, Department of Research for Humanized Model, Central Institute for Experimental Medicine and Life Science (CIEM), Kanagawa, Japan.
  • Drug Metabolism and Toxicology, Faculty of Pharmaceutical Sciences, Kanazawa University, Kakuma-machi, Kanazawa, Japan; WPI Nano Life Science Institute (WPI-NanoLSI), Kanazawa University, Kakuma-machi, Kanazawa, Japan.…

Förderung

  • Ministry of Education, Culture, Sports, Science and Technology
  • Mochida Memorial Foundation for Medical and Pharmaceutical Research
  • Kanazawa University

Zitieren

APA

Sato, R., Nakano, M., Higuchi, Y., Uehara, S., Yoneda, N., Suemizu, H., Nakajima, M., & Fukami, T. (2026). CYP1A2 and ADH1C contribute to abacavir aldehyde intermediate formation in the human liver. Drug Metabolism and Disposition, 54(8), 100348. https://doi.org/10.1016/j.dmd.2026.100348

Vancouver

Sato R, Nakano M, Higuchi Y, Uehara S, Yoneda N, Suemizu H, et al. CYP1A2 and ADH1C contribute to abacavir aldehyde intermediate formation in the human liver. Drug Metabolism and Disposition. 2026;54(8):100348. doi:10.1016/j.dmd.2026.100348

BibTeX
@article{Sato2026,
  author = {Sato, Rei and Nakano, Masataka and Higuchi, Yuichiro and Uehara, Shotaro and Yoneda, Nao and Suemizu, Hiroshi and Nakajima, Miki and Fukami, Tatsuki},
  title = {CYP1A2 and ADH1C contribute to abacavir aldehyde intermediate formation in the human liver},
  journal = {Drug Metabolism and Disposition},
  year = {2026},
  volume = {54},
  number = {8},
  pages = {100348},
  doi = {10.1016/j.dmd.2026.100348}
}
Kostenlos starten →